A phase I study of NY-ESO-1b peptide plus montanide ISA-51 in patients with ovarian, primary peritoneal, or fallopian tube cancer expressing NY-ESO-1 or LAGE-1
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cancer vaccine NY-ESO-1; Montanide ISA-51
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Pharmacodynamics
- 24 Feb 2021 Biomarkers information updated
- 22 Dec 2009 Actual end date (Jul 2006) added as reported by ClinicalTrials.gov.
- 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.